Transdermal Delivery: Challenges and Opportunities
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (20 March 2025) | Viewed by 15160
Special Issue Editor
Interests: skin delivery; dermal delivery; transdermal delivery; nanocarriers; liposomes; penetration enhancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The skin, being the largest organ in humans, which covers the whole body, has become recognized as an important drug delivery route. Unlike most other organs in the body, the skin can be reached directly. Therefore, there is a great interest in the skin as a site of drug application, both for dermal and transdermal drug delivery. Transdermal delivery involves the application of a drug to the skin in order to achieve systemically active drug levels to treat systemic diseases. Transdermal drug delivery systems (TDDS) offer a number of advantages compared to conventional drug delivery systems, leading to systemic drug effects. TDDS enable the drugs to be directly delivered to the systemic circulation, circumventing hepatic first-pass effects and avoiding the interaction of the drug with the gastrointestinal tract. Furthermore, TDDS act as a “depot”, controlling the rate of drug input over a prolonged period of time and ensuring constant plasma levels. Regarding drugs with a narrow therapeutic margin, their undesirable side effects, particularly those associated with pulsed peak plasma levels, may be reduced via the use of a TDDS. In addition, the use of a TDDS enables the dose frequency to be reduced. It is worth noting that TDDS are non-invasive, i.e., they avoid needle delivery, which is associated with pain and patient phobia (involved with intravenous therapy), and TDDS drugs can be self-administered. The aforementioned advantages of TDDS lead to enhanced patient compliance.
However, the effectiveness of transdermal drug delivery is often hindered by challenges such as the low permeability of the most apical layer of the skin, the stratum corneum, leading to limitations in the skin permeation of drugs and thus low therapeutic effectiveness due to the insufficient plasma levels of drugs. In addition, unfavorable drug properties such as inadequate solubility and partition coefficient (log P), as well as their high molecular weight values, limit the efficacy of transdermal drug delivery. Only few drug molecules yield skin permeability coefficients sufficiently high to develop clinically active plasma levels. Thus, the market for transdermal patches comprises patches with only few low-molecular-weight drugs.
Therefore, significant efforts have been devoted to developing strategies to overcome the impermeability of intact human skin, which provides the main barrier for drug penetration. These strategies involve chemical (formulation-based) and physical penetration enhancement techniques. Chemical penetration enhancement methods involve the manipulation of the drug or vehicle in order to enhance the drug diffusion through the skin; this also includes the use of different nanocarriers (e.g., vesicles, nanoparticles, etc.). Among physical methods, iontophoresis, electroporation, and ultrasound are the most studied enhancement methods.
The primary focus of this Special Issue is to address the opportunities and challenges associated with transdermal drug delivery and to demonstrate how various percutaneous penetration enhancement strategies can overcome these challenges, thereby improving the therapeutic efficacy of TDDS.
Dr. Nina Dragićević
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- transdermal drug delivery
- nanocarrier
- iontophoresis
- electroporation
- ultrasound
- liposome
- nanoparticle
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
